You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 6,797,732

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,797,732

Title:	Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
Abstract:	An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Inventor(s):	Virkki; Matti (Masala, FI), Vahervuo; Kari (Espoo, FI), Ritala; Marja (Espoo, FI), Partanen; Marja (Espoo, FI), Niskanen; Mervi (Espoo, FI), Lintulaakso; Jarmo (Espoo, FI), Laaksonen; Marja (Masala, FI), Kervinen; Lasse (Helsinki, FI), Kallioinen; Sari (Espoo, FI)
Assignee:	Orion Corporation (Espoo, FI)
Application Number:	10/223,298
Patent Claims:	1. A stable oral solid composition comprising pharmacologically effective amounts of active agents consisting of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient other than microcrystalline cellulose. 2. The composition according to claim 1, wherein the composition is in the form of a tablet. 3. The composition according to claim 1, wherein the composition does not comprise microcrystalline cellulose. 4. The composition according to claim 2, wherein the composition does not comprise microcrystalline cellulose. 5. The composition according to claim 1, wherein the composition comprises at least one pharmaceutically acceptable excipient other than a surface active agent. 6. The composition according to claim 1, wherein the composition comprises at least one pharmaceutically acceptable excipient other than silica. 7. The composition according to claim 1, wherein the composition comprises a disintegrant as the excipient. 8. The composition according to claim 7, wherein the disintegrant is sodium starch glycolate or croscarmellose sodium. 9. The composition according to claim 1, wherein the composition comprises a sugar alcohol as the excipient. 10. The composition according to claim 1, wherein the composition comprises hydrogenated vegetable oil as the excipient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.